Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist. It exhibits high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6, dopamine D1-4, muscarinic M1-5, and adrenergic α1 receptors. It is classified as an atypical antipsychotic.
- Targets multiple receptors including 5-HT, dopamine, mAChR, and adrenergic receptors
- Inhibits proliferation in glioblastoma cell lines
- Enhances temozolomide's anti-tumor activity
- Induces apoptosis and necrosis in glioblastoma cell lines
- Suitable for research in neurological disease and cancer